



12 November 2025

Alphagan® P 1.5 (brimonidine tartrate 1.5%) Eye Drops – Discontinuation Notice

Dear Pharmacist,

AbbVie wishes to inform you that ALPHAGAN® P 1.5 eye drops (Brimonidine tartrate), currently registered in Australia for primary open-angle glaucoma (POAG), will be discontinued due to a global manufacturing decision. This discontinuation is not related to efficacy, safety, or any regulatory concerns. Full unrestricted supply is expected until January 31, 2026, after which wholesaler availability may differ according to local stock levels.

To ensure continuous patient care, ALPHAGAN® P 1.0 eye drops (Brimonidine tartrate, 1.0mg/mL) has been registered by the TGA and will be available from 1 February 2026. ALPHAGAN® P 1.0 contains the same active ingredient at a lower concentration^{1,2}.

ALPHAGAN® P 1.0 will not be funded by the PBS and will be available as a private script at the same price point as ALPHAGAN® P 1.5. For further details, including Product and Consumer Information, please refer to:


- [TGA Website](#)
- [AbbVie.com](#)

Transition guidelines for patient management will be provided approximately one month before ALPHAGAN® P 1.0's launch in February 2026.

If you require additional assistance, please contact:

- For any further medical information, please contact medinfoanz@abbvie.com or call 1800 252 224
- For all product supply enquiries please contact AbbVie Operations via email supportanz@abbvie.com

Yours Sincerely,



Leah Howison

References:

1. ALPHAGAN® P 1.0 Product Information.
2. Cantor LB et al. *Curr Med Res Opin.* 2008; 24(7): 2035–2043.

AbbVie Pty Ltd	+61 2 9035 8600
Level 7	(OFFICE)
241 O'Riordan	1800 564 716 (FAX)
Street	abbvie.com.au
Mascot	ABN: 48 156 384 262
NSW 2020	AU-ALP-250019
Australia	October 2025